Efficacy and mechanism of decitabine combined with vitamin C in the treatment of myelodysplastic syndrome
Objective:To evaluate the efficacy and mechanism of decitabine combined with vitamin C in the treatment of myelodysplastic syndrome(MDS).Methods:78 newly diagnosed MDS patients in our hospital from September 2020 to September 2022 were selected as the study subjects.They were divided into two groups based on the different chemotherapy methods chosen by the patients.The observation group(38 cases)received treatment with decitabine combined with vitamin C regimen,while the control group(40 cases)received treatment with decitabine alone.The therapeutic effects of the two groups were evaluated.All patients underwent MDS related mutation gene testing to analyze the characteristics of mutation genes and their relationships with therapeutic efficacy.Results:The total response rate of the observation group was higher than that of the control group(76.32%vs 55.00%,P<0.05).The detection rate of gene mutations in MDS patients was 71.79%,and the treatment effectiveness rate of TET2 mutation patients was higher than that of the control group(100.00%vs 55.56%,P<0.05).Conclusion:MDS patients are prone to genetic mutations,and the combination of decitabine and vitamin C is more effective and has a higher response rate in the treatment of MDS compared to using decitabine alone.The mechanism may be related to the activation of tumor cell TET2 expression by vitamin C which enhances demethylation.